Articles published by HMNC Holding GmbH

HMNC Brain Health announces $50 million first closing of Series B financing and a strategic partnership with MEDICE

June 15, 2026

From HMNC Holding GmbH

Via GlobeNewswire

Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation

October 15, 2025

From HMNC Holding GmbH

Via GlobeNewswire

HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam

October 13, 2025

From HMNC Holding GmbH

Via GlobeNewswire

HMNC Brain Health Announces Phase 2 Results from OLIVE Trial in Major Depressive Disorder (MDD) with Genetically Guided Precision Approach

August 05, 2025

From HMNC Holding GmbH

Via GlobeNewswire

HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder

July 22, 2025

From HMNC Holding GmbH

Via GlobeNewswire

Tickers SPRB

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder

January 10, 2025

From HMNC Holding GmbH

Via GlobeNewswire

HMNC Brain Health Collaborates with the Austrian Institute of Technology and the Danube Private University to Win Grant from the Austrian Research Promotion Agency

December 11, 2024

From HMNC Holding GmbH

Via GlobeNewswire

HMNC Brain Health to Present Advances in Precision Psychiatry and Psychedelics at CNS Summit 2024 in Boston

October 31, 2024

From HMNC Holding GmbH

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.